Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: A phase II study based on surgical reassessment

The purpose of this study was to determine whether adding the anti-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib to carboplatin/paclitaxel improved pathologic complete response (pCR) at reassessment surgery in epithelial ovarian, fallopian tube, or primary peritoneal ca...

Full description

Saved in:
Bibliographic Details
Published in:Gynecologic oncology Vol. 119; no. 3; pp. 451 - 456
Main Authors: Blank, Stephanie V., Christos, Paul, Curtin, John P., Goldman, Noah, Runowicz, Carolyn D., Sparano, Joseph A., Liebes, Leonard, Chen, Helen X., Muggia, Franco M.
Format: Journal Article
Language:English
Published: United States Elsevier Inc 01.12.2010
Subjects:
ISSN:0090-8258, 1095-6859, 1095-6859
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first